PAREXEL International Corp (NASDAQ:PRXL)
The Company provides a range of expertise in clinical research, medical communications services, consulting, and informatics and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
medical with upside
Recs
It's never too early to go Christmas shopping. Picking a broad basket of stocks that seem favorable when expecting a short term bull rally.
Recs
Another sell-off buying opportunity.
Recs
Because I can bet the sector will win, without the risk of crappy management....Pfizer *cough cough*
Recs
Taking today's (1/27) 30% gain on this stock and going Thumbs Down for a few weeks.
Recs
Recs
Considerable backlog exists for the services of this clinical research and marketing company whose stock has taken an unjustified hit of late.
Recs
One of few stocks in the world that operates in an industry outside of the FIRE sector of economy (FIRE = Financial, Insurance & Real Estate).
In fact, not only does this company operate outside of FIRE, but it offers good future dividend potential, great valuation to earning potential, and is a great pick within its respective sector.
These are companies I'd put my money into right now rather than into residential real estate, apartment buildings, other stocks, commodities, or bonds. Few may fail, but just as many will quadruple within the next decade.
BUY.
bullish on nws, hnsn, prxl, aray, chp, navi, hero, bas, pcz, cybx, feic, ebay
These picks are within this CAPs account that is market neutral - all longs are offset by a short. All long & short picks are diversified across industries & world location to limit downside exposure. This CAPS account will maintain at the very least 20 picks and at the very most 80 picks. Picks will be ended in long/short pairs to remain neutral.
Recs
This stock has consistently outperformed the S&P 500 and seems to be undervalued due to the recent sell off. No debt makes them very attractive in this market.
Recs
Clinical research. 4 star.
Recs
Breakout today from cup-with-handle, right at confluence of 50-day and 200-day MAs
Recs
Biggest gainer in equity potential rank
Recs
it will keep growing
Recs
This stock is set to split in the middle of March. With $1 billion in sales, and anticipated earnings of almost 30% for both this year and next, PRXL will be a great investment.
Recs
Great sector to be in. Similar to an oil-service stock- you get all of the benefits with minimal risk. Easy outperform.
Recs
Parexel Intl. Corp, a bio/pharmaceutical srvcs. company, provides clincal research, medical communication srvcs, consulting and tech. products to medical industries worldwide, with a $1.55 B Market cap; its Diversified Svcs sector has been 16th best of 31 sectors the last 12 mos. at -5.6%. Zack's rank is a "2", PEG ratios of 1.15 and 0.91 for the next two years fwd show value left for price increasing on top of the 25.6% rise over the last six months. Earnings reported on 4/28/08; last two quarters it has averaged a +23.3 percent surprise and 25% year to year sales growth, to $943 million. Price/Sales ratio is now at 1.64 and this year's earnings est. have increased from 0.82 to 0.84. Current buy range of 27 - 27.75; short term target of $29.95; long term of $34.50 . Vector Vest currently rates them a "Buy" at 27.40 with a P/E of 16.21, and a value of 37.31, and a stop loss at 25.40. They just split 2 for 1 and now might back off a little after the run-up to the split and I am looking for a decent entry point.
Recs
Week #3 - Tuesday: 'Stock Pick of the Day'
Recs
R&D will be hugh in 08 which is what this firm is all about
Recs
The Cramer Effect,
Recs
One of the top companys in this field with good growth numbers.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 23 : 1 2 Next »